Alvogen   Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: Pine Brook NJ United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2011
NCT01421563
First Marketed Drug
2008
hexamethylenetetramine
First NDA Approval
2022
venlaxafine (Effexor)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ALMATICA | ALVOGEN | ALVOGEN INC | Alvogen Korea | ALVOGEN MALTA | ALVOGEN PINE BROOK | Alvogen Pine Brook LLC